This article is available to subscribers. Subscribe now. Already have an account? Sign in

Clinical PracticeFree Preview

Essential Thrombocythemia

List of authors.
  • Ayalew Tefferi, M.D.,
  • and Animesh Pardanani, M.B., B.S., Ph.D.

Essential thrombocythemia is associated with increased risks of bleeding and thrombosis. Estimation of the risk of thrombosis is based on history of thrombosis, presence of the JAK2 V617F mutation, age, and cardiovascular risk. Treatment commonly involves low-dose aspirin; therapy is used in patients with high thrombotic risk.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

No potential conflict of interest relevant to this article was reported.

Author Affiliations

From the Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Address reprint requests to Dr. Tefferi at the Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at .

Print Subscriber? Activate your online access.